Othman Al‐Sawaf

6.4k total citations · 1 hit paper
54 papers, 747 citations indexed

About

Othman Al‐Sawaf is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Othman Al‐Sawaf has authored 54 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Genetics, 30 papers in Pathology and Forensic Medicine and 21 papers in Immunology. Recurrent topics in Othman Al‐Sawaf's work include Chronic Lymphocytic Leukemia Research (48 papers), Lymphoma Diagnosis and Treatment (30 papers) and Immunodeficiency and Autoimmune Disorders (18 papers). Othman Al‐Sawaf is often cited by papers focused on Chronic Lymphocytic Leukemia Research (48 papers), Lymphoma Diagnosis and Treatment (30 papers) and Immunodeficiency and Autoimmune Disorders (18 papers). Othman Al‐Sawaf collaborates with scholars based in Germany, United States and United Kingdom. Othman Al‐Sawaf's co-authors include Michael Hallek, Kirsten Fischer, Christoph Jan Wruck, Athanassios Fragoulis, Thomas Pufe, Yuet Wai Kan, Barbara Eichhorst, Konrad L. Streetz, Tim Clarner and Anna‐Maria Fink and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Othman Al‐Sawaf

50 papers receiving 737 citations

Hit Papers

Chronic lymphocytic leukemia: 2022 update on diagnostic a... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
    2021 213 citations Michael Hallek, Othman Al‐Sawaf American Journal of Hematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Othman Al‐Sawaf Germany 12 469 344 216 201 114 54 747
Irmgard Andresen Germany 15 208 0.4× 137 0.4× 169 0.8× 214 1.1× 212 1.9× 41 852
Roberta Bertelli Italy 18 199 0.4× 237 0.7× 356 1.6× 196 1.0× 50 0.4× 37 1.1k
Dongfeng Zeng China 17 155 0.3× 83 0.2× 225 1.0× 130 0.6× 276 2.4× 66 699
Stefan Franz Switzerland 6 112 0.2× 134 0.4× 249 1.2× 131 0.7× 43 0.4× 7 881
I Marschitz Austria 12 110 0.2× 77 0.2× 280 1.3× 250 1.2× 101 0.9× 17 616
Anna Rogers United States 13 173 0.4× 65 0.2× 236 1.1× 83 0.4× 233 2.0× 15 679
Chengshan Guo China 16 127 0.3× 195 0.6× 115 0.5× 189 0.9× 452 4.0× 31 759
Bin Fu China 14 163 0.3× 67 0.2× 314 1.5× 53 0.3× 249 2.2× 29 647
Kosei Oshima United States 6 413 0.9× 54 0.2× 374 1.7× 259 1.3× 591 5.2× 7 1.1k
Dong Lin China 14 72 0.2× 77 0.2× 263 1.2× 130 0.6× 134 1.2× 67 714

Countries citing papers authored by Othman Al‐Sawaf

Since Specialization
Citations

This map shows the geographic impact of Othman Al‐Sawaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Othman Al‐Sawaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Othman Al‐Sawaf more than expected).

Fields of papers citing papers by Othman Al‐Sawaf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Othman Al‐Sawaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Othman Al‐Sawaf. The network helps show where Othman Al‐Sawaf may publish in the future.

Co-authorship network of co-authors of Othman Al‐Sawaf

This figure shows the co-authorship network connecting the top 25 collaborators of Othman Al‐Sawaf. A scholar is included among the top collaborators of Othman Al‐Sawaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Othman Al‐Sawaf. Othman Al‐Sawaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simon, Florian, Othman Al‐Sawaf, John F. Seymour, & Barbara Eichhorst. (2024). Surrogate endpoints in mature B-cell neoplasms – meaningful or misleading?. Leukemia. 39(1). 25–28.
2.
Σταματόπουλος, Κώστας, Šárka Pavlová, Othman Al‐Sawaf, et al.. (2024). Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities. HemaSphere. 8(7). e113–e113. 2 indexed citations
3.
4.
Al‐Sawaf, Othman, et al.. (2024). Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease. Current Oncology Reports. 26(2). 136–146. 3 indexed citations
5.
Al‐Sawaf, Othman, Min‐Hua Jen, Lisa M. Hess, et al.. (2023). Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 109(6). 1866–1873. 3 indexed citations
6.
Samineni, Divya, Leonid Gibiansky, Bei Wang, et al.. (2022). Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Advances in Therapy. 39(8). 3635–3653. 7 indexed citations
7.
Al‐Sawaf, Othman, Michael Hallek, & Kirsten Fischer. (2022). The role of minimal residual disease in chronic lymphocytic leukemia.. PubMed. 20(2). 97–103. 1 indexed citations
8.
Al‐Sawaf, Othman, John F. Seymour, Arnon P. Kater, & Kirsten Fischer. (2021). Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America. 35(4). 775–791. 4 indexed citations
9.
Davids, Matthew S., Kirsten Fischer, Sandra Robrecht, et al.. (2021). ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 2634–2634. 8 indexed citations
10.
Al‐Sawaf, Othman. (2020). Characteristics and Outcome of Patients with Chronic Lymphocytic Leukaemia and Partial Response to Venetoclax-Obinutuzumab. 3 indexed citations
11.
Al‐Sawaf, Othman, Sandra Robrecht, Jasmin Bahlo, et al.. (2020). Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 35(1). 169–176. 62 indexed citations
12.
Al‐Sawaf, Othman, Barbara Eichhorst, & Michael Hallek. (2020). Chronische lymphatische Leukämie. Der Internist. 61(3). 277–287.
13.
14.
Al‐Sawaf, Othman, Alexandra Bazeos, Sandra Robrecht, et al.. (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology. 94(9). 1002–1006. 5 indexed citations
15.
16.
Al‐Sawaf, Othman, et al.. (2018). Pelvic cellulitis caused by Raoultella planticola in a neutropenic patient. Journal of Infection and Chemotherapy. 25(4). 298–301. 1 indexed citations
17.
Al‐Sawaf, Othman, Kirsten Fischer, Anja Engelke, et al.. (2017). Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Design Development and Therapy. Volume11. 295–304. 12 indexed citations
18.
Al‐Sawaf, Othman, Kirsten Fischer, Barbara Eichhorst, & Michael Hallek. (2016). Targeted Therapy of CLL. Oncology Research and Treatment. 39(12). 768–778. 7 indexed citations
19.
Al‐Sawaf, Othman, Athanassios Fragoulis, Christian Rosén, et al.. (2014). Nrf2 Protects Against TWEAK-mediated Skeletal Muscle Wasting. Scientific Reports. 4(1). 3625–3625. 23 indexed citations
20.
Sönmez, Tolga Taha, Othman Al‐Sawaf, Gerald Brandacher, et al.. (2013). A Novel Laser-Doppler Flowmetry Assisted Murine Model of Acute Hindlimb Ischemia-Reperfusion for Free Flap Research. PLoS ONE. 8(6). e66498–e66498. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irmgard Andresen Breakdown of academic impact, for papers by Roberta Bertelli Breakdown of academic impact, for papers by Dongfeng Zeng Breakdown of academic impact, for papers by Stefan Franz Breakdown of academic impact, for papers by I Marschitz Breakdown of academic impact, for papers by Anna Rogers Breakdown of academic impact, for papers by Chengshan Guo Breakdown of academic impact, for papers by Bin Fu Breakdown of academic impact, for papers by Kosei Oshima Breakdown of academic impact, for papers by Dong Lin
Rankless by CCL
2026